Literature DB >> 20031388

High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy.

Patrizia Nanni1, Giordano Nicoletti, Lorena Landuzzi, Stefania Croci, Annalisa Murgo, Arianna Palladini, Agnese Antognoli, Marianna L Ianzano, Valeria Stivani, Valentina Grosso, Sauveur-Michel Maira, Carlos García-Echeverría, Katia Scotlandi, Carla De Giovanni, Pier-Luigi Lollini.   

Abstract

Immunodeficient animal models are invaluable tools to investigate the metastatic propensity of human tumours. However residual immune responses, in particular natural killer (NK) cells, severely hamper the traffic and growth of human tumour cells. We studied whether a genetically modified mouse host lacking T, B and NK immunity allowed an improved expression of the metastatic phenotype of malignant human tumours. Metastatic spread of a panel of human sarcoma cell lines was studied in double knockout Rag2(-/-);gammac(-/-) mice in comparison with NK-depleted nude mice. Rag2(-/-);gammac(-/-) mice receiving intravenous (i.v.) or subcutaneous (s.c.) human sarcoma cell lines developed extensive multiorgan metastases. Metastatic efficiency in Rag2(-/-);gammac(-/-) was superior than in nude mice in terms of both metastatic sites and metastasis number. Metastatic growth in Rag2(-/-);gammac(-/-) mice was faster than that in nude mice, thus allowing an earlier metastasis evaluation. Most human sarcomas metastasised in the liver of Rag2(-/-);gammac(-/-) mice, a kind of organ preference undetectable in nude mice and specific of sarcomas, as several carcinoma cell lines failed to colonise the liver of Rag2(-/-);gammac(-/-) mice, independently of their metastatic spread to other sites. In vitro analysis of the molecular mechanisms of liver metastasis of sarcomas implicated liver-produced growth and motility factors, in particular the insulin-like growth factor (IGF) axis. NVP-BEZ235, a specific inhibitor of downstream signal transduction targeting PI3K and mTOR, strongly inhibited liver metastasis of human sarcoma cells. In conclusion, the Rag2(-/-);gammac(-/-) mouse model allowed the expression of human metastatic phenotypes inapparent in conventional immunodeficient mice and the preclinical testing of appropriate targeted therapies. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20031388     DOI: 10.1016/j.ejca.2009.11.018

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  20 in total

1.  EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.

Authors:  Christopher H Evans; Fangjun Liu; Ryan M Porter; Regina P O'Sullivan; Taha Merghoub; Elaine P Lunsford; Kyle Robichaud; Frans Van Valen; Stephen L Lessnick; Mark C Gebhardt; James W Wells
Journal:  Clin Cancer Res       Date:  2012-08-09       Impact factor: 12.531

2.  Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.

Authors:  Marianna L Ianzano; Stefania Croci; Giordano Nicoletti; Arianna Palladini; Lorena Landuzzi; Valentina Grosso; Dario Ranieri; Massimiliano Dall'Ora; Ilaria Santeramo; Milena Urbini; Carla De Giovanni; Pier-Luigi Lollini; Patrizia Nanni
Journal:  Oncotarget       Date:  2014-01-15

3.  Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.

Authors:  Chintda Santiskulvong; Gottfried E Konecny; Mirela Fekete; Kuang-Yui Michael Chen; Amer Karam; David Mulholland; Carol Eng; Hong Wu; Min Song; Oliver Dorigo
Journal:  Clin Cancer Res       Date:  2011-03-03       Impact factor: 12.531

4.  Caveolin-1 modulates the ability of Ewing's sarcoma to metastasize.

Authors:  Miguel Sáinz-Jaspeado; Laura Lagares-Tena; Jaime Lasheras; Fariba Navid; Carlos Rodriguez-Galindo; Silvia Mateo-Lozano; Vicente Notario; Xavier Sanjuan; Xavier Garcia Del Muro; Angels Fabra; Oscar M Tirado
Journal:  Mol Cancer Res       Date:  2010-11       Impact factor: 5.852

5.  Preclinical HER-2 Vaccines: From Rodent to Human HER-2.

Authors:  Pier-Luigi Lollini; Carla De Giovanni; Patrizia Nanni
Journal:  Front Oncol       Date:  2013-06-10       Impact factor: 6.244

6.  Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor.

Authors:  Patrizia Nanni; Giordano Nicoletti; Arianna Palladini; Stefania Croci; Annalisa Murgo; Marianna L Ianzano; Valentina Grosso; Valeria Stivani; Agnese Antognoli; Alessia Lamolinara; Lorena Landuzzi; Emmanuelle di Tomaso; Manuela Iezzi; Carla De Giovanni; Pier-Luigi Lollini
Journal:  PLoS One       Date:  2012-06-21       Impact factor: 3.240

7.  Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas.

Authors:  Lorena Landuzzi; Marianna L Ianzano; Giordano Nicoletti; Arianna Palladini; Valentina Grosso; Dario Ranieri; Massimiliano Dall'Ora; Elena Raschi; Roberta Laranga; Marco Gambarotti; Piero Picci; Carla De Giovanni; Patrizia Nanni; Pier-Luigi Lollini
Journal:  Oncotarget       Date:  2014-12-15

8.  Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines.

Authors:  Cecilia Garofalo; Mariantonietta Capristo; Caterina Mancarella; Hadas Reunevi; Piero Picci; Katia Scotlandi
Journal:  Front Endocrinol (Lausanne)       Date:  2015-05-13       Impact factor: 5.555

9.  Human responses against HER-2-positive cancer cells in human immune system-engrafted mice.

Authors:  C De Giovanni; G Nicoletti; L Landuzzi; F Romani; S Croci; A Palladini; A Murgo; A Antognoli; M L Ianzano; V Stivani; V Grosso; M Iezzi; L Stramucci; E Barbieri; R M Lemoli; P Nanni; P-L Lollini
Journal:  Br J Cancer       Date:  2012-08-28       Impact factor: 7.640

10.  Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.

Authors:  Patrizia Nanni; Valentina Gatta; Laura Menotti; Carla De Giovanni; Marianna Ianzano; Arianna Palladini; Valentina Grosso; Massimiliano Dall'ora; Stefania Croci; Giordano Nicoletti; Lorena Landuzzi; Manuela Iezzi; Gabriella Campadelli-Fiume; Pier-Luigi Lollini
Journal:  PLoS Pathog       Date:  2013-01-31       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.